Amorfix in-licenses novel technology to begin therapeutic program for neurodegenerative diseases
07-Feb-2006
The SOD1 targets were discovered by Dr. Neil Cashman, the company's Chief Scientific Officer, in his former academic laboratory at the University of Toronto, Centre for Research in Neurodegenerative Diseases. The University subsequently assigned all rights to Dr. Cashman who has licensed the technology to Amorfix.
Organizations
University of Toronto
Amorfix Life Sciences
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.